Shares of ResMed Inc. RMD slumped 0.35% to $228.69 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to 5,881.63 and Dow ...

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

These 2 ASX shares are set to deliver a strong set of earnings in the next quarter according to experts. Let's dive in.

Let's see what steps you could take to build a winning portfolio. The post How I'd build a winning portfolio by investing in ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The contact-free sleep monitoring systems market is projected to grow at an 8.1% CAGR, reaching $214.7 million by 2033 from ...

During five years of share price growth, ResMed achieved compound earnings per share (EPS) growth of 21% per year. This EPS growth is higher than the 8% average annual increase in the share price.

Morgans's healthcare analyst Iain Wilkie describes 2024 as "pretty patchy" for the ASX healthcare sector, which has ...

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

The well-known name from a former "hot tech" era is attempting to bounce from the late October/early November new low.

With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. So we asked ...

CorMedix is a member of the Medical sector. This group includes 1020 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The ...